<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-046110</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Epidermal growth factor receptor inhibitors side effects</dc:title>
<dc:description xml:lang="en">Epidermal growth factor receptor (EGFR) inhibitors are a new group of drugs used in the treatment of several malignancies. Three molecules are approved at the moment: gefitinib and erlotinib for the treatment of non-small-cell lung cancer, and cetuximab for colorectal cancer. These drugs originate cutaneous side effects with a high frequency: acneiform rashes, paronychia and generalized xerodermia. In this paper we review these common side effects and how to manage them</dc:description>
<dc:creator>Guhl, Guillermo</dc:creator>
<dc:creator>González-de Arriba, Ana</dc:creator>
<dc:creator>Daudén, Esteban</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Los inhibidores del receptor del factor de crecimiento epidérmico (EGFR) son una nueva clase de fármacos para el tratamiento de diversas neoplasias. En la actualidad existen tres fármacos aprobados: gefitinib y erlotinib para el carcinoma de pulmón no de células pequeñas, y cetuximab para el cáncer de colon. Estas sustancias producen con mucha frecuencia efectos adversos cutáneos entre los que se encuentran entre otros las erupciones acneiformes, las paroniquias, la xerodermia generalizada. En el presente trabajo se realiza una revisión de estos efectos adversos así como de su tratamiento</dc:description>
<dc:source>Actas Dermosifiliogr;97(5): 296-310, jun. 2006. ilus</dc:source>
<dc:identifier>ibc-046110</dc:identifier>
<dc:title xml:lang="es">Efectos cutáneos de los inhibidores del receptor del factor de crecimiento epidérmico</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d6079^s22012</dc:subject>
<dc:subject>^d6079^s22016</dc:subject>
<dc:subject>^d30873^s22012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d3965</dc:subject>
<dc:subject>^d6793^s22073</dc:subject>
<dc:subject>^d6794^s22073</dc:subject>
<dc:subject>^d30873^s22016</dc:subject>
<dc:subject>^d13379^s22073</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d24479^s22073</dc:subject>
<dc:subject>^d14133^s22073</dc:subject>
<dc:subject>^d10493^s22012</dc:subject>
<dc:subject>^d14983^s22012</dc:subject>
<dc:subject>^d4896^s22021</dc:subject>
<dc:subject>^d15382^s22012</dc:subject>
<dc:subject>^d4896^s22020</dc:subject>
<dc:subject>^d30694^s22012</dc:subject>
<dc:subject>^d14983^s22016</dc:subject>
<dc:subject>^d15382^s22016</dc:subject>
<dc:type>article</dc:type>
<dc:date>200606</dc:date>
</metadata>
</record>
</ibecs-document>
